MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study

MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) AHSCT (Allogeneic Hematopoietic Stem Cell Transplant) Safety Study

NCT02427178•Michio Hirano, MD

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

Interventions

Hematopoietic Allogeneic Stem Cells

Key Dates

Start Date

March 1, 2015

Primary Completion Date

June 1, 2022

Completion Date

June 1, 2023

Last Updated

August 1, 2022

Sponsors

Lead Sponsor

Michio Hirano, MD

Collaborators

Cornell University
National Institute of Neurological Disorders and Stroke (NINDS)

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 1, 2022Data synced to Clareo: April 26, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions